Proteomics of human liver membrane transporters: a focus on fetuses and newborn infants

[1]  Ioannis P. Androulakis,et al.  Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine , 2016, Journal of Pharmacokinetics and Pharmacodynamics.

[2]  B. Meibohm,et al.  Special Section on Pediatric Drug Disposition and Pharmacokinetics Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver , 2016 .

[3]  R. Evers,et al.  Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex , 2014, Drug Metabolism and Disposition.

[4]  D. Keppler,et al.  Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver , 2009, Hepatology.

[5]  J. S. Leeder,et al.  Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development , 2016, Drug Metabolism and Disposition.

[6]  K. Verhoeckx,et al.  Drug-Drug Interactions between Rosuvastatin and Oral Antidiabetic Drugs Occurring at the Level of OATP1B1 , 2013, Drug Metabolism and Disposition.

[7]  D. Tibboel,et al.  Ontogeny of Human Hepatic and Intestinal Transporter Gene Expression during Childhood: Age Matters , 2014, Drug Metabolism and Disposition.

[8]  O. Fardel,et al.  Regulation of drug transporter mRNA expression by interferon‐γ in primary human hepatocytes , 2011, Fundamental & clinical pharmacology.

[9]  A. Vinks,et al.  Developmental Changes in Hepatic Organic Cation Transporter OCT1 Protein Expression from Neonates to Children , 2017, Drug Metabolism and Disposition.

[10]  J. Brockmöller,et al.  Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. , 2013, Biochemical pharmacology.

[11]  P. Smith,et al.  Higher clearance of micafungin in neonates compared with adults: role of age‐dependent micafungin serum binding , 2011, Biopharmaceutics & drug disposition.

[12]  D. Tibboel,et al.  Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics , 2015, Clinical Pharmacokinetics.

[13]  Sieto Bosgra,et al.  Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  M. Kool,et al.  Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.

[15]  Curtis D. Klaassen,et al.  Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation , 2010, Pharmacological Reviews.

[16]  Luis Serrano,et al.  Correlation of mRNA and protein in complex biological samples , 2009, FEBS letters.

[17]  Yvonne S. Lin,et al.  Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype. , 2013, Journal of pharmaceutical sciences.

[18]  D. Adams,et al.  Hepatic expression and cellular distribution of the glucose transporter family. , 2012, World journal of gastroenterology.

[19]  S. Caritis,et al.  Hepatobiliary Disposition of 17-OHPC and Taurocholate in Fetal Human Hepatocytes: A Comparison with Adult Human Hepatocytes , 2013, Drug Metabolism and Disposition.

[20]  B. Blumberg,et al.  Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues , 2005, Molecular and Cellular Endocrinology.

[21]  Y. Lai,et al.  Interindividual Variability in Hepatic Expression of the Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2): Quantification by Liquid Chromatography/Tandem Mass Spectrometry , 2012, Drug Metabolism and Disposition.

[22]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[23]  T. Skaar,et al.  Age‐Related Changes in MicroRNA Expression and Pharmacogenes in Human Liver , 2015, Clinical pharmacology and therapy.

[24]  G. Giaccone,et al.  Multidrug resistance gene (P-glycoprotein) expression in the human fetus. , 1992, American Journal of Pathology.

[25]  B. Meibohm,et al.  Physiologically Based Pharmacokinetic (PBPK) Modeling in Children , 2012, Clinical pharmacology and therapeutics.

[26]  D. Tibboel,et al.  Special Section on Pediatric Drug Disposition and Pharmacokinetics Proteomic Analysis of the Developmental Trajectory of Human Hepatic Membrane Transporter Proteins in the First Three Months of Life , 2016 .

[27]  J. Venhorst,et al.  Generation of Bayesian prediction models for OATP-mediated drug-drug interactions based on inhibition screen of OATP1B1, OATP1B1∗15 and OATP1B3. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[28]  Z. Riches,et al.  Lobular Distribution and Variability in Hepatic ATP Binding Cassette Protein B1 (ABCB1, P-gp): Ontogenetic Differences and Potential for Toxicity , 2017, Pharmaceutics.

[29]  X. Chu,et al.  Ontogeny of Hepatic Drug Transporters as Quantified by LC‐MS/MS Proteomics , 2016, Clinical pharmacology and therapeutics.

[30]  Mei-Hwei Chang,et al.  Developmental expression of canalicular transporter genes in human liver , 2005 .

[31]  F. Guimiot,et al.  mRNA expression of MDR1 and major metabolising enzymes in human fetal tissues. , 2009, Drug metabolism and pharmacokinetics.

[32]  V. Lukacova,et al.  Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group , 2015, Clinical pharmacology and therapeutics.

[33]  M. Laughon,et al.  Medication Use in the Neonatal Intensive Care Unit , 2013, American Journal of Perinatology.

[34]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[35]  D. Tibboel,et al.  SLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn Infants , 2016, Therapeutic drug monitoring.

[36]  H. Rosing,et al.  The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Jandl,et al.  Differential expression of ABC transporters (MDR1, MRP1, BCRP) in developing human embryos , 2011, Journal of Molecular Histology.

[38]  Ronald N Hines,et al.  The ontogeny of drug metabolism enzymes and implications for adverse drug events. , 2008, Pharmacology & therapeutics.

[39]  T. Andersson,et al.  Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects , 2013, Clinical pharmacology and therapeutics.

[40]  H. M. Bender,et al.  Role of blood‐brain barrier P‐glycoprotein in limiting brain accumulation and sedative side‐effects of asimadoline, a peripherally acting analgaesic drug , 1999, British journal of pharmacology.